|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0030705,
umls-concept:C0037313,
umls-concept:C0079809,
umls-concept:C0205322,
umls-concept:C0242485,
umls-concept:C0301630,
umls-concept:C0439423,
umls-concept:C0687676,
umls-concept:C0751249,
umls-concept:C0936012,
umls-concept:C1518681,
umls-concept:C1617723,
umls-concept:C1696465,
umls-concept:C1704243
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2008-8-11
|
|
pubmed:abstractText |
Ramelteon is a selective MT1/MT2 melatonin receptor agonist approved by the US Food and Drug Administration for insomnia treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0149-2918
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1316-23
|
|
pubmed:meshHeading |
pubmed-meshheading:18691991-Adult,
pubmed-meshheading:18691991-Chronic Disease,
pubmed-meshheading:18691991-Female,
pubmed-meshheading:18691991-Humans,
pubmed-meshheading:18691991-Indenes,
pubmed-meshheading:18691991-Male,
pubmed-meshheading:18691991-Randomized Controlled Trials as Topic,
pubmed-meshheading:18691991-Receptor, Melatonin, MT1,
pubmed-meshheading:18691991-Receptor, Melatonin, MT2,
pubmed-meshheading:18691991-Sleep,
pubmed-meshheading:18691991-Sleep Initiation and Maintenance Disorders,
pubmed-meshheading:18691991-Substance Withdrawal Syndrome,
pubmed-meshheading:18691991-Time Factors
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Ramelteon 8 mg/d versus placebo in patients with chronic insomnia: post hoc analysis of a 5-week trial using 50% or greater reduction in latency to persistent sleep as a measure of treatment effect.
|
|
pubmed:affiliation |
Takeda Pharmaceuticals North America, Inc., Deerfield, Illinois 60015, USA. lmini@tpna.com
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
